|
Market Cap (3-Jul) $3,153,122 (199th) |
Close (30-Jun) $0.091 |
Volume (30-Jun) 50,159,971 |
Shortsold (19-Jun) 392,315,164 (5.25%) (41st) |
|
52w High $2.75 |
52w Low $0.340 |
P/E - |
EPS -0.6 |
IMU released this announcement to the ASX on 1 July 2022, 11:44. The announcement is not marked as price sensitive, and is 2 page(s) in length and 186.32kb in size.
You can view all announcements from IMU and see how they appear on a price chart on the announcements page.
At the date of this announcement, IMU was 5.687% short sold according to ASIC data. It was ranked the 31st most shorted stock on the ASX. It remains ranked 41st as of the latest reported data (19 June 2025).
| Other Recent Announcements from IMU | |
|---|---|
| Change of Director's Interest Notice | 30 June 2023, 16:33 |
| HER-Vaxx induced antibodies correlated with tumour reduction | 30 June 2023, 8:40 |
| Imugene PD1-Vaxx patent extended to 2040 | 29 June 2023, 8:39 |
| Appointment of Dr Sharon Yavrom as Clinical Scientist | 1 July 2022, 11:44 |
| Investor Webinar - Final HER-Vaxx Overall Survival Results | 27 June 2022, 9:15 |
| Final HER-Vaxx Phase 2 Trial Overall Survival Results | 27 June 2022, 8:24 |
| Change of Director's Interest Notice - CW | 14 June 2022, 9:10 |
You must be logged in to post a reply.
Imugene 